Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 8/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22484304 | 0.95 | XIAP (0.50) | AGTR2AGTR1XIAPNTSR2NTSR1 | |
| SCHEMBL22484305 | 0.95 | XIAP (0.50) | AGTR2AGTR1XIAPNTSR2NTSR1 | |
| SCHEMBL25524189 | 0.90 | XIAP (0.53) | AGTR2AGTR1XIAPNTSR2NTSR1 | |
| SCHEMBL29401292 | 0.87 | XIAP (0.47) | AGTR2AGTR1XIAPNTSR2NTSR1 | |
| SCHEMBL29873831 | 0.85 | XIAP (0.51) | AGTR2AGTR1XIAPNTSR2NTSR1 | |
| SCHEMBL30067143 | 0.84 | NTSR2 (0.51) | NTSR2NTSR1SORT1REN | |
| SCHEMBL29592298 | 0.83 | KEAP1 (0.46) | NTSR2NTSR1CALCRLREN | |
| SCHEMBL24217628 | 0.83 | CMA1 (0.44) | AGTR2AGTR1XIAPCALCRL | |
| SCHEMBL24217630 | 0.83 | CMA1 (0.44) | AGTR2AGTR1XIAPCALCRL | |
| SCHEMBL30532202 | 0.82 | XIAP (0.53) | AGTR2AGTR1XIAPNTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | AGTR2 1842/4885AGTR1 1890/4885XIAP 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.